Who We Are At a Glance

• Global IP Developed by renowned Nephrologist, Dr. Daniel Batlle, the Earle, del Greco Levin endowed Professor of Medicine and Hypertension, Northwestern University, Feinberg School of Medicine, Chicago, IL
• A spinout from Northwestern University
• A novel platform – breakthrough proprietary suite of ACE2 proteins which are shorter than the natural ACE2, the main receptor for SARS-CoV-2 and further modified to enhance the duration of action
• Positive results, and PK data in animal models and data in human cell models; known safety of class of the parent ACE2 molecule
• Supportive scientific evidence and publications describing the mechanism of action
• Expert team developing to lead growth from preclinical to clinical development